CD28 expression is increased in venom allergic patients but is not modified by specific immunotherapy

Clinical and Experimental Allergy

Volumn 26, Issue 10, 1996, Pages 1119-1124

  Tsicopoulos, A ^a,b   Labalette, M ^b   Akoum, H ^a   Duez, C ^a   Wallaert, B ^a,b   Dessaint, J P ^b   Tonnel, A B ^a,b  

^a INSTITUT PASTEUR DE LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

CD28; Rush venom immunotherapy; T lymphocyte; Tolerance

Indexed keywords

ALLERGEN; CD28 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOTHERAPY; INSECT ALLERGY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; ANTIGENS, CD28; ARTHROPOD VENOMS; BEE VENOMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; MALE; MIDDLE AGED; T-LYMPHOCYTES; WASP VENOMS;

EID: 0029810107     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.1996.tb00497.x     Document Type: Article

References (34)

1. Jenkins M, Pardoll D, Mizugushi J, Quill H, Schwanz R. T-cell unresponsiveness in vivo and in vitro: fine specificity of induction and molecular characterization of the unresponsive state. Immunol Rev 1987; 95:113-25.
2. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci 1990; 87:5031-5.
3. Gimmi CD, Freeman GJ, Gribben JG et al. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci 1991; 88:6575 9.
4. Koulova L, Clark EA, Shu G, Dupont B. The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells. J Exp Med 1991; 173:759-62.
5. Handing FA, McArthur JG, Gross JA, Raulet DH. Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992; 356:607 9.
6. Tan P, Anasetti C. Hansen JA et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/ BB1. J Exp Med 1993; 177:165-73.
7. Chen CY, Nabavi N. In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-I/ B7-2. Immunity 1994; 1:147 54.
8. Lenschow DJ, Zeng Y. Thistlethwaite JR et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4-Ig. Science 1992; 257:789 92.
9. Wierenga EA, Snoek M. Jansen HM et al. Human atopen-specific types 1 and 2 T helper cell clones. J Immunol 1991; 147:2942-9.
10. Freeman GJ, Lombard DB, Gimmi CD et al. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. J Immunol 1992; 149:3795-801.
11. Lindsten T, June CH, Ledbetter JA, Stella G, Thompson CB. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 1989; 244:339 43.
12. De Boer M, Kasran A. Kwekkeboom J et al. Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells. Eur J Immunol 1993; 23:3120 5.
13. Seder RA, Germain RN, Linsley PS, Paul WE. CD28-mediated costimulation of interleukin 2 (IL-2) production plays a critical role in T cell priming for IL-4 and Interferon gamma production. J Exp Med 1994; 179:299-304.
14. Walter H, Schepensn S, Vanwauwe J, Deboer M. Ligation of CD28 on resting T cells by its ligand B7 results in the induction of both Th1- and Th2-type cytokines. Eur Cytokine Netw 1994; 5:13-21.
15. Minty A, Chalon P. Derocq JM et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 1993; 362:248 50.
16. Life P, Aubry JP, Estoppey S, Schnuriger V, Bonnefoy JY. CD28 functions as an adhesion molecule and is involved in the regulation of human IgE synthesis. Eur J Immunol 1995; 25:333 9.
17. Shahinian A, Pfeffer K, Lee KP et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 1993; 261:609 12.
18. Hunt KJ, Valentine MD, Sobotka AK et al. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978; 299:157-61.
19. Rocklin RE, Sheffer AL, Greineder DK, Melmon KL. Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med 1980; 302:1213 9.
20. Gatien JG, Merler E, Colten HR. Allergy to ragweed antigen E: effect of specific immunotherapy on the reactivity of human T lymphocytes in vitro. Clin Immunol Immunopathol 1975; 4:32-7.
21. Hiratani H, Muto K, Oshiday HOS, Kasei M. Lymphocyte responsiveness to Dermatophagoïdes farinae extract in mite-sensitive patients: effect of immunotherapy on cellular proliferative response and specific immunoglobulin E antibody. J Allergy Clin Immunol 1981; 68:205 11.
22. Ledru E, Pestel J. Tsicopoulos A et al. Lymphocyte-mediated regulation of platelet activation during desensitization in patients with hymenoptera hypersensitivity. Clin Exp Immunol 1988; 73:198-203.
23. Akoum H, Tsicopoulos A, Vorng H et al. Venom immunotherapy modulates interleukin-4 and interferons-γ messenger RNA expression of peripheral T lymphocytes. Immunol 1996; 87:593-98.
24. Jutel M, Pichler WJ. Skrhic D et al. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated cultures. J Immunol 1995; 154:4188 94.
25. McHugh SM, Deighton J, Stewart AG, Lachmann PJ, Ewan PW. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 1995; 25:828 38.
26. Birnbaum J, Charpin D, Vervloet D. Rapid hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy 1993; 23:226 30.
27. Tilmant L, Dessaint JP, Tsicopoulos A, Tonnel AB, Capron A. Concomitant augmentation of CD4+ CD45R+ suppressor/inducer subset and diminution of CD4+ CDw29+ helper/inducer subset during rush hyposensitization in hymenoptera venom allergy. Clin Exp Immunol 1989; 76:13 8.
28. Lake RA, O'Hehir RE, Verhoef A, Lamb JR. CD28 mRNA rapidly decays when activated T cells are functionally anergized with specific peptide. Int Immunol 1993; 5:461 6.
29. Freeman GJ, Boussiotis VA. Anumanthan A et al. B7-1 and B7-2 do not deliver identical eostimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 1995; 2:523 32.
30. Kuchroo VK, Das MP. Brown JA et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1 Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995; 80:707 18.
31. Linsley PS, Bradshavv J, Urnes M, Grosmaire L, Ledbetter JA. CD28 engagement by B7 BB-1 induces transient down-regulation of CD28 synthesis and prolonged unresponsiveness to CD28 signalling. J Immunol 1993; 150:3161 9.
32. Friccius H, Siegels HP, Rehbein A, Schlotz E, Pawelec G. Induction of hyporesponsiveness in human lymphocytes-T despite their expression of both the co-receptor CD28 and its ligand B7. Cell Immunol 1993; 151:283 90.
33. Azuma M, Phillips JH, Lanier LL. CD28-T lymphocytes. Antigenic and functional properties. J Immunol 1993; 150: 1147 59.
34. Li SG, Ottenhoff TH. Van den Eisen, P et al. Human suppressor T cell clones lack CD28. Eur J Immunol 1990; 20:1281 8.